406 related articles for article (PubMed ID: 27467728)
1. Biomarkers in melanoma.
Griewank KG
Scand J Clin Lab Invest Suppl; 2016; 245():S104-12. PubMed ID: 27467728
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD
JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250
[TBL] [Abstract][Full Text] [Related]
3. Melanoma Treatments: Advances and Mechanisms.
Marzuka A; Huang L; Theodosakis N; Bosenberg M
J Cell Physiol; 2015 Nov; 230(11):2626-33. PubMed ID: 25899612
[TBL] [Abstract][Full Text] [Related]
4. Combinatorial Therapies in Melanoma: MAPK Inhibitors and Beyond.
Zhou AY; Johnson DB
Am J Clin Dermatol; 2018 Apr; 19(2):181-193. PubMed ID: 28861871
[TBL] [Abstract][Full Text] [Related]
5. Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists.
Kakavand H; Wilmott JS; Long GV; Scolyer RA
Pathology; 2016 Feb; 48(2):194-202. PubMed ID: 27020392
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint inhibitors and targeted therapies for metastatic melanoma: A network meta-analysis.
Pasquali S; Chiarion-Sileni V; Rossi CR; Mocellin S
Cancer Treat Rev; 2017 Mar; 54():34-42. PubMed ID: 28189914
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous Complications of Targeted Melanoma Therapy.
de Golian E; Kwong BY; Swetter SM; Pugliese SB
Curr Treat Options Oncol; 2016 Nov; 17(11):57. PubMed ID: 27645330
[TBL] [Abstract][Full Text] [Related]
8. Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma.
Kroon P; Gadiot J; Peeters M; Gasparini A; Deken MA; Yagita H; Verheij M; Borst J; Blank CU; Verbrugge I
Cancer Immunol Immunother; 2016 Jun; 65(6):753-63. PubMed ID: 27160390
[TBL] [Abstract][Full Text] [Related]
9. Developing melanoma therapeutics: overview and update.
Korman JB; Fisher DE
Wiley Interdiscip Rev Syst Biol Med; 2013; 5(3):257-71. PubMed ID: 23408545
[TBL] [Abstract][Full Text] [Related]
10. Melanoma: understanding relevant molecular pathways as well as available and emerging therapies.
McKibbin T
Am J Manag Care; 2015 Sep; 21(10 Suppl):S224-33. PubMed ID: 26619296
[TBL] [Abstract][Full Text] [Related]
11. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
Ott PA; Hodi FS; Robert C
Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
[TBL] [Abstract][Full Text] [Related]
12. Gaining momentum: New options and opportunities for the treatment of advanced melanoma.
Michielin O; Hoeller C
Cancer Treat Rev; 2015 Sep; 41(8):660-70. PubMed ID: 26096079
[TBL] [Abstract][Full Text] [Related]
13. Advanced Melanoma: Current Treatment Options, Biomarkers, and Future Perspectives.
Rozeman EA; Dekker TJA; Haanen JBAG; Blank CU
Am J Clin Dermatol; 2018 Jun; 19(3):303-317. PubMed ID: 29164492
[TBL] [Abstract][Full Text] [Related]
14. Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care.
Goldman C; Tchack J; Robinson EM; Han SW; Moran U; Polsky D; Berman RS; Shapiro RL; Ott PA; Osman I; Zhong H; Pavlick AC; Wilson MA
Oncology; 2017; 93(3):164-176. PubMed ID: 28601879
[TBL] [Abstract][Full Text] [Related]
15. [Great advances in the systemic treatment in malignant melanoma patients].
Ullenhag G; Hansson J; Ny L
Lakartidningen; 2017 May; 114():. PubMed ID: 28485771
[TBL] [Abstract][Full Text] [Related]
16. Targeting BRAF in melanoma: biological and clinical challenges.
Mandalà M; Voit C
Crit Rev Oncol Hematol; 2013 Sep; 87(3):239-55. PubMed ID: 23415641
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy in managing metastatic melanoma: which treatment when?
Amaral T; Meraz-Torres F; Garbe C
Expert Opin Biol Ther; 2017 Dec; 17(12):1523-1538. PubMed ID: 28891339
[TBL] [Abstract][Full Text] [Related]
18. CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations.
Camacho LH
Cancer Med; 2015 May; 4(5):661-72. PubMed ID: 25619164
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy in melanoma: Recent advances and future directions.
Franklin C; Livingstone E; Roesch A; Schilling B; Schadendorf D
Eur J Surg Oncol; 2017 Mar; 43(3):604-611. PubMed ID: 27769635
[TBL] [Abstract][Full Text] [Related]
20. Update on systemic therapy for advanced cutaneous melanoma and recent development of novel drugs.
Swe T; Kim KB
Clin Exp Metastasis; 2018 Aug; 35(5-6):503-520. PubMed ID: 30019239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
